Blood Pressure Drug Shows Promise Against Deadly Antibiotic Resistant Bacteria
Finn's Take· TL;DR- Blood pressure drug candesartan cilexetil kills dangerous MRSA bacteria by disrupting cell membranes in lab and animal studies.
- Repurposing existing, inexpensive medication could accelerate treatment development since safety profile already established and approved for human use.
- Researchers optimizing similar compounds for human trials as antibiotic-resistant infections kill 35,000+ Americans annually, outpacing new drug development.
Unexpected Medical Breakthrough
Scientists have discovered that a widely prescribed blood pressure medication could become a powerful weapon against one of the most dangerous antibiotic-resistant bacteria threatening modern medicine. Researchers at the Houston Methodist Research Institute have shown that candesartan cilexetil could help stop methicillin-resistant Staphylococcus aureus, or MRSA .
MRSA results in more than 70,000 severe infections and 9,000 deaths in the US every year , making it one of the most pressing public health challenges. This type of staph bacteria has evolved to survive many commonly used antibiotics and now spreads in communities as well as hospitals, causing skin infections, pneumonia, and even life-threatening bloodstream infections .
How the Drug Works Against Superbugs
In laboratory and animal studies, the blood pressure medicine disrupted the bacteria's cell membrane, interfering with cellular function and ultimately killing the bacteria by latching onto, penetrating, and disrupting the MRSA cell membrane . This approach represents a fundamentally different strategy from traditional antibiotics.
The membrane is a critical part of the cell, providing structure and acting as a gatekeeper to the cell's insides . By targeting this essential structure, the drug bypasses the resistance mechanisms that make MRSA so difficult to treat with conventional antibiotics. In mouse models, candesartan cilexetil significantly reduced the bacterial burden, providing evidence that the drug could hold promise for fighting MRSA in humans .
Advantages of Repurposing Existing Medication
The drug is inexpensive and already widely used to treat high blood pressure and heart failure, making it an especially attractive option if its effectiveness against MRSA is confirmed in human trials . Because it is already approved and widely used, its safety profile is well understood, which could significantly shorten the timeline for clinical use in a new role .
This discovery comes at a crucial time when attempts to develop new drugs aren't keeping pace with the problem of antibiotic resistance. Antibiotic-resistant bacteria continue to outpace modern medicine, causing more than 2.8 million infections and over 35,000 deaths each year in the United States alone .
Future Research and Clinical Applications
The research team is developing similar drugs, chemically tweaking candesartan cilexetil to make new compounds that are more effective and potentially have fewer side effects, and hoping to work with pharmaceutical or biotech companies to further test the compounds in human trials .
The researchers remain optimistic about translating their laboratory success into real-world treatments. "We are trying to get this from benchside to bedside," said study co-author Nagendran Tharmalingam. This research represents a promising example of how existing medications might be repurposed to address some of medicine's most challenging problems, potentially offering hope for patients facing life-threatening infections that resist conventional treatment.